Intravesical bacillus Calmette-Guérin versus mitomycin C for Ta and T1 bladder cancer

42Citations
Citations of this article
19Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows: To assess the effects of bacillus Calmette-Guérin (BCG) intravesical therapy compared to mitomycin C (MMC) intravesical therapy for treating Ta and T1 bladder cancer in adults.

Cite

CITATION STYLE

APA

Schmidt, S., Kunath, F., Coles, B., Draeger, D. L., Krabbe, L. M., Dersch, R., … Meerpohl, J. J. (2015). Intravesical bacillus Calmette-Guérin versus mitomycin C for Ta and T1 bladder cancer. Cochrane Database of Systematic Reviews, 2015(11). https://doi.org/10.1002/14651858.CD011935

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free